Cascade blue | 500906-09-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Cascade blue
• 英文别名: [4-[[4-(diethylamino)phenyl]-[4-(ethylamino)naphthalen-2-yl]methylidene]cyclohexa-2,5-dien-1-ylidene]-diethylazanium
• CAS: 500906-09-2
• 化学式: C33H40N3+
• 分子量: 478.7
• InChiKey: CZPLANDPABRVHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.7
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  18.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• COMPOSITION AND METHODS RELATED TO MODIFICATION OF 5 HYDROXYMETHYLCYTOSINE (5-hmC)
  申请人：THE UNIVERSITY OF CHICAGO

  公开号：US20200102616A1

  公开（公告）日：2020-04-02

  The present invention relates generally to the field of molecular biology. More particularly, it concerns methods and compositions for detecting, evaluating, and/or mapping 5-hydroxymethyl-modified cytosine bases within a nucleic acid molecule.
• US8741567B2
  申请人：——

  公开号：US8741567B2

  公开（公告）日：2014-06-03
• [EN] COMPOSITIONS AND METHODS FOR DIABETES TREATMENT<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DU DIABÈTE
  申请人：MASSACHUSETTS GEN HOSPITAL

  公开号：WO2021195344A2

  公开（公告）日：2021-09-30

  Described are compositions and methods for determining the propensity of a subject with diabetes (e.g., type 1 diabetes) to benefit from treatment with Bacillus Calmette-Guerin (BCG). Using the compositions and methods of the disclosure, a subject with diabetes (e.g., type 1 diabetes) may be identified as likely to respond to BCG therapy on the basis, for example, of a determination that the subject was young (e.g., less than 40 years of age) at the time of onset of the diabetes. Additionally, or alternatively, the subject may be identified as likely to respond to BCG therapy based on a determination that the subject exhibits a reduced rate of glucose uptake, an elevated rate of oxidative phosphorylation, and/or a reduced rate of aerobic glycolysis, for example, as compared to a healthy subject (e.g., a subject without diabetes). The compositions and methods of the disclosure can additionally be used to administer BCG to subjects identified as likely to respond to treatment with a composition comprising BCG.